Engene (ENGN) announces CMO resignation

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, announced today that Dr. Raj Pruthi resigned from his role as Chief Medical Officer on June 3, 2025. Dr. Pruthi’s resignation as Chief Medical Officer will take effect on June 16, 2025. He will be supporting the organization to ensure an orderly transition of his responsibilities before he departs. The Company intends to reallocate Dr. Pruthi’s responsibilities to the Company’s other urology and clinical experts. The Company thanks Dr. Pruthi for his dedication and service and wishes him the best in his future endeavors.

You May Also Be Interested In

• JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
• Elemental Royalty closes four-asset acquisition, expands credit line to $250M
• Vertiv launches pre-engineered AI infrastructure platform SmartIT